Clinical Trial Update: Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a rebeccamycin analogue in patients with refractory stage III/IV ovarian epithelial cancer has been terminated. The update provides s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Rebeccamycin analogue (rebeccamycin analogue)

Snippet

Sponsor: Northwestern University | Conditions: Ovarian Cancer | Phase 2 | Status: TERMINATED